91.61

1.55% 1.40

After Hours: 91.61

Corcept Therapeutics Inc (CORT)

Overview News Price History Option Chain Financials Why CORT Down? Discussions Forecast

Corcept Therapeutics Inc stock is traded at $91.61, with a volume of 1.17M. It is up +1.55% in the last 24 hours and up +26.15% over the past month. Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Previous Close:

$90.21

Open:

$90.29

24h Volume:

1.17M

Relative Volume:

1.03

Market Cap:

$9.83B

Revenue:

$769.10M

Net Income/Loss:

$46.67M

P/E Ratio:

261.74

EPS:

0.35

Net Cash Flow:

$119.79M

1W Performance:

+4.23%

1M Performance:

+26.15%

6M Performance:

+156.04%

1Y Performance:

+26.76%

1-Day Range:

$89.73

$92.83

1-Week Range:

$86.04

$92.83

52-Week Range:

$28.66

$92.83

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name

Corcept Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

650.688.8803

Address

101 REDWOOD SHORES PARKWAY, REDWOOD CITY

Employee

730

Twitter

Next Earnings Date

2026-07-30

Latest SEC Filings

CORT's Discussions on Twitter

Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CORT Corcept Therapeutics Inc	91.61	9.33B	769.10M	46.67M	119.79M	0.35
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-13-26	Upgrade	UBS	Neutral → Buy
Mar-26-26	Upgrade	Wolfe Research	Underperform → Peer Perform
Dec-31-25	Downgrade	Wolfe Research	Peer Perform → Underperform
Dec-16-25	Initiated	UBS	Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-06-23	Upgrade	Truist	Hold → Buy
Apr-11-23	Initiated	SVB Securities	Market Perform
Apr-04-23	Initiated	Piper Sandler	Overweight
Feb-15-23	Downgrade	Jefferies	Buy → Hold
Aug-01-22	Downgrade	Truist	Buy → Hold
Jul-27-22	Upgrade	Jefferies	Hold → Buy
Jun-27-22	Resumed	Canaccord Genuity	Buy
Feb-02-22	Initiated	Canaccord Genuity	Buy
Jan-28-22	Initiated	Truist	Buy
Aug-05-20	Downgrade	Jefferies	Buy → Hold
Sep-24-19	Initiated	Jefferies	Buy
Sep-06-19	Initiated	H.C. Wainwright	Buy
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral
Aug-10-18	Reiterated	Stifel	Hold
May-31-18	Downgrade	Stifel	Buy → Hold
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy
Aug-31-17	Initiated	Stifel	Buy
Feb-02-17	Initiated	Ladenburg Thalmann	Buy
Apr-21-15	Initiated	FBR Capital	Outperform
Jan-13-14	Downgrade	Stifel	Buy → Hold
Aug-09-13	Downgrade	Janney	Buy → Neutral
Aug-09-13	Downgrade	Ladenburg Thalmann	Buy → Neutral
Feb-21-12	Reiterated	JMP Securities	Mkt Outperform
Jan-06-10	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-17-08	Initiated	Rodman & Renshaw	Mkt Outperform
Jun-21-07	Upgrade	Punk, Ziegel & Co	Mkt Perform → Accumulate

View All

Corcept Therapeutics Inc Stock (CORT) Latest News

Jul 01, 2026

CORTCorcept Therapeutics Inc Volatility & Greeks - Finviz

Jul 01, 2026

Jun 30, 2026

Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView

Jun 30, 2026

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits

Jun 30, 2026

Enterprise value to revenue forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView

Jun 30, 2026

Price to earnings forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView

Jun 30, 2026

Jun 29, 2026

Corcept sinks after FDA rejects drug to treat hypertension - MSN

Jun 29, 2026

Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com

Jun 29, 2026

Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index - marketscreener.com

Jun 29, 2026

CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits

Jun 29, 2026

Jun 28, 2026

CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits

Jun 28, 2026

Jun 27, 2026

Corcept gives FDA new relacorilant data in resubmitted application - Cushing's Disease News

Jun 27, 2026

Jun 25, 2026

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - PR Newswire

Jun 25, 2026

Number of shareholders of Corcept Therapeutics Incorporated. – BX:HTD - TradingView

Jun 25, 2026

Corcept Therapeutics Incorporated. Actuals & Estimates (NASDAQ:CORT) - TradingView

Jun 25, 2026

HTD Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026